

## FAST AND EFFECTIVE OPTIMIZATION OF MRM METHODS FOR LC/MS/MS ANALYSIS OF PEPTIDES

Joanne Mather, Paul D. Rainville, Erin Chambers, and Robert S. Plumb  
Waters Corporation, Milford, MA, U.S.

### INTRODUCTION

Peptide-based biotherapeutic compounds are used in a wide range of fields including endocrinology, hematology, and neurology to treat a variety of conditions from acromegaly to Parkinson's disease.

Biotherapeutic drugs are often synthetic or modified versions of an endogenous peptide, designed to mimic or enhance activity of these naturally-occurring compounds, and they are therefore well-tolerated by the body. They exhibit high specificity, efficacy, and low toxicity profiles.<sup>1</sup> Bioanalysis must be performed to measure pharmacokinetics/pharmacodynamics (PK/PD), metabolic fate, and bioequivalence for regulatory submissions. There are currently more than 40 peptide drugs on the market as well as more than 400 in late stage clinical trials.<sup>2</sup>

Peptides have traditionally been analyzed by ligand-binding assays such as ELISA or RIA, which can be time-consuming and expensive to develop the antibodies and assays.

LC/MS/MS is a well-understood technique for the analysis of small molecules; use of the same platform for bioanalysis of peptides offers:

- Broad dynamic range – 3 to 4 orders of magnitude
- Accuracy
- Universal Method – One analytical technique for many diverse peptides
- Fast method development

### Analytical challenges

Determining optimum LC/MS/MS operating conditions for peptide bioanalysis generally requires some trial and error, which for non-experts can be time-consuming and daunting. In particular, choosing the optimum ionization mode has traditionally involved physically

changing the MS source. To further complicate matters, it is common to see 2+, 3+, 4+, and 5+ charge states, depending on the size of the peptide. This can make decisions in multiple reaction mode (MRM) MS more challenging as product ions may appear at higher  $m/z$  values than precursors. Thus a wider  $m/z$  range needs to be scanned for fragment identification. A mass range of up to 2000 amu is required to have the ability to select higher  $m/z$  precursors for fragmentation, for example, 3+ precursor ions of larger peptides.

In this application note we describe the use of Waters' innovative IntelliStart™ Software and its use with the ACQUITY UPLC® and tandem quadrupole Xevo™ TQ MS systems to rapidly develop an MRM method for peptides/small proteins, with subsequent incorporation into an LC/MS/MS method for separation, detection, and quantitation.



Figure 1. ACQUITY UPLC and Xevo TQ MS.

## EXPERIMENTAL

A generalized workflow for the development of a peptide MRM method in bioanalysis is shown in Figure 2. IntelliStart incorporates software and hardware that greatly simplify the task of selecting the best parameters for monitoring peptides.

IntelliStart will automatically:

- Monitor system parameters
- Perform mass calibration and set resolution
- Tune source conditions to each compound
- Generate an MS Method for SIR or MRM
- Check LC/MS system performance
- Enable automated generation of optimized SIR and/or MRM methods for new compounds




Figure 2. Workflow for the development of a peptide MRM method.




Figure 3. Molecular Mass Calculator in MassLynx Software.

Setting up IntelliStart to select the optimum conditions for MRM monitoring of a peptide is easily carried out. Since there can be many charged states, the first step is to use the Molecular Mass Calculator embedded within MassLynx™ Software (Figure 3) to calculate the possible charge state m/z values for a compound.

After entering a compound's formula, the number of required charge states is generated, dependent on the peptide's size. The calculator will then display the possible m/z values.

The next step is simply to input the name of the compound, the m/z values, and check the Multiply Charged Parents box in the IntelliStart setup page (Figure 4).

IntelliStart will now optimize conditions as detailed in Figure 2 and generate a report (Figure 5) detailing the conditions for the best MRM for the peptide. The report is automatically saved for future reference and incorporation into routine analysis.

In this example, compounds are sampled from an on-board vial via fluidics, so no external syringe driver is required.

Tuning can be carried out in "combined infusion" mode to optimize the method at an appropriate LC flow rate and solvent composition. As peptides form different charge states depending on pH, a thorough investigation of mobile phase pH will allow the optimum conditions to be generated.




Figure 4. IntelliStart's Sample Tune browser.

Compound	Formula/Mass		Parent m/z	Cone Voltage	Daughters	Collision Energy	Ion Mode
bivalirudin	727.6	1	727.63	16	943.80	18	ES+
		2	727.63	16	1025.35	16	ES+
		3	727.63	16	766.14	16	ES+
		4	727.63	16	356.23	26	ES+
		5	727.63	16	721.69	12	ES+
bivalirudin	1091	1	1090.84	44	356.23	48	ES+
		2	1090.84	44	650.40	24	ES+
		3	1090.84	44	1531.07	36	ES+
		4	1090.84	44	519.30	34	ES+
		5	1090.84	44	1025.22	24	ES+

Figure 5. Section of an IntelliStart report.

The IntelliStart report details parameters determined by the system. This report is automatically saved for future reference. IntelliStart also automatically generates an MS method that can then be used in routine analysis. tion of mobile phase pH will allow for the optimum conditions to be generated.

## CONCLUSIONS

- IntelliStart Software provides an efficient, rapid, reproducible, and effective approach to developing MRM methods for peptide assays.
- The software intelligently scans for multiple charge states of the parent peptide and scans for product ions at higher m/z values than the parents.
- The Xevo TQ MS allows a wide mass range, up to 2000 Da, to be scanned for fragment identification of larger peptides.

## References

1. Bladon C. Pharmaceutical Chemistry: Therapeutic Aspects of Biomolecules. Wiley and Sons. West Sussex, England, 2002.
2. Bioscience Technology. January, 2002.
3. Rainville PD, Mather J, Plumb RS. Automated Development of MRM Methods for Bioanalytical Assays. Waters Application Note. 2008; 720002569en.
4. Mather J, Rainville PD, Plumb RS, Baynham G. Automated System Check for Bioanalytical Assays: IntelliStart. Waters Application Note. 2008; 720002620en.

# Waters

THE SCIENCE OF WHAT'S POSSIBLE.™



Waters and ACQUITY UPLC are registered trademarks of Waters Corporation. Xevo and The Science of What's Possible are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

©2009 Waters Corporation. Printed in the U.S.A.  
October 2009 720003254EN AG-PDF

**Waters Corporation**  
34 Maple Street  
Milford, MA 01757 U.S.A.  
T: 1 508 478 2000  
F: 1 508 872 1990  
[www.waters.com](http://www.waters.com)